This project will generate a new type of molecular data from a cohort of PD patients and age-matched controls and has the potential to yield novel PD biomarkers. Further, it will translate the LiP-MS technology to a clinical setting. Upon completion of the project, we plan to make the technology available for clinical applications through the mass spectrometric (MS) platform recently established by the PHRT executive committee. LiP-MS analyses can be applied to generate molecular data for a variety of other diseases, such as cancer.